KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Payables (2017 - 2026)

Moderna (MRNA) has disclosed Payables for 10 consecutive years, with $161.0 million as the latest value for Q1 2026.

  • For Q1 2026, Payables fell 28.76% year-over-year to $161.0 million; the TTM value through Mar 2026 reached $161.0 million, down 28.76%, while the annual FY2025 figure was $317.0 million, 21.73% down from the prior year.
  • Payables hit $161.0 million in Q1 2026 for Moderna, down from $317.0 million in the prior quarter.
  • Across five years, Payables topped out at $520.0 million in Q4 2023 and bottomed at $161.0 million in Q1 2026.
  • Average Payables over 5 years is $311.5 million, with a median of $310.0 million recorded in 2023.
  • Year-over-year, Payables surged 2387.5% in 2022 and then tumbled 52.96% in 2024.
  • Moderna's Payables stood at $487.0 million in 2022, then grew by 6.78% to $520.0 million in 2023, then dropped by 22.12% to $405.0 million in 2024, then dropped by 21.73% to $317.0 million in 2025, then tumbled by 49.21% to $161.0 million in 2026.
  • According to Business Quant data, Payables over the past three periods came in at $161.0 million, $317.0 million, and $267.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.